Retina Implant AG Announces Change in Leadership
REUTLINGEN, Germany, July 4, 2016 /PRNewswire/ --
Following 12 years of successful development at Retina Implant AG, Dr. Walter-G. Wrobel, CEO of the company, has announced his resignation by mutual consent. The resignation will take effect on September 30, 2016.
(Photo: http://photos.prnewswire.com/prnh/20160701/385790 )
Dr. Wrobel’s departure, along with recent CE-approval of the new RETINA IMPLANT Alpha AMS, indicates a new era for the company; one that will be heavily influenced by navigating the challenges of distribution.
Wrobel said of his departure: “This is the right time for me to hand over operational responsibility. It has been a very thrilling and satisfying time. I hope that Retina implant AG has as much success in the future as they have now.”
The supervisory board expressed their thanks to Dr. Wrobel for his exceptional and treasured contribution to the company’s success. The chairman, Prof. Zrenner stated: “Without his intensive personal commitment and strategical foresight, we would never have gotten this far. With his exceptional manner, he formed a company of highly innovative retinal implants from a scientific project.”
Dipl.-Kfm. Reinhard Rubow, who has been on the board for 13 years, will step up to lead Retina Implant AG as sole executive director from October 1, 2016.
To keep updated on Retina Implant AG follow us on Twitter @RetinaImplant.
About Retina Implant AG
Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner, professor of Ophthalmology, University of Tübingen, Germany and his colleagues in 2003 with private investors with the goal of developing a fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting human patients in 2005 and started a second, larger clinical trial in 2010. In July 2013, Retina Implant’s wireless subretinal implant technology, Alpha IMS, received CE mark. To learn more, visit http://www.retina-implant.de/.
MSLGROUP:
Sarah Herbert
+44(0)203-219-8708
sarah.herbert@mslgroup.com
Retina Implant, AG.:
Reinhard Rubow
+49-7121 | 36403-100
Reinhard.Rubow@retina-implant.de
